KOD
Company Description
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (229.97M) | (176.21M) | (260.49M) | (333.82M) | (266.99M) | (133.10M) | (47.37M) | (41.44M) | (27.94M) | (17.13M) |
| EPS | -4.32 | -3.35 | -4.97 | -6.39 | -5.16 | -2.91 | -1.23 | -1.16 | -1.05 | -2.30 |
| Free Cash Flow | (136.51M) | (117.72M) | (195.61M) | (253.82M) | (245.57M) | (90.43M) | (39.58M) | (29.61M) | (17.86M) | (16.82M) |
| FCF / Share | -2.57 | -2.24 | -3.73 | -4.86 | -4.74 | -1.98 | -1.05 | -0.83 | -0.67 | -2.26 |
| Operating CF | (136.01M) | (117.32M) | (154.18M) | (206.46M) | (182.27M) | (83.43M) | (39.15M) | (29.03M) | (17.66M) | (16.05M) |
| Total Assets | 351.53M | 335.58M | 479.37M | 666.63M | 904.22M | 1.07B | 358.87M | 92.19M | 3.24M | 12.11M |
| Total Debt | 159.18M | 70.34M | 181.63M | 187.73M | 179.94M | 77.40M | 1.94M | 0 | 10.08M | 185,000 |
| Cash & Equiv | 209.86M | 168.07M | 285.51M | 190.43M | 731.51M | 944.40M | 211.80M | 88.25M | 1.40M | 9.62M |
| Book Value | 157.38M | 150.29M | 265.78M | 436.17M | 663.32M | 860.75M | 345.36M | 86.83M | (68.74M) | (41.08M) |
| Return on Equity | -1.46 | -1.17 | -0.98 | -0.77 | -0.40 | -0.15 | -0.14 | -0.48 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (65.64M) | (58.16M) | (56.74M) | (61.46M) | (54.31M) | (57.46M) | (44.10M) | (43.95M) | (45.12M) | (43.04M) | (59.52M) | (50.01M) |
| EPS | -1.05 | -0.94 | -1.04 | -1.16 | -1.03 | -1.09 | -0.84 | -0.84 | -0.86 | -0.82 | -1.13 | -0.95 |
| Free Cash Flow | (46.59M) | (40.95M) | (39.42M) | (32.94M) | (34.81M) | (29.35M) | (30.19M) | (21.36M) | (26.54M) | (39.62M) | (59.72M) | (32.99M) |
| FCF / Share | -0.74 | -0.66 | -0.74 | -0.62 | -0.66 | -0.56 | -0.57 | -0.41 | -0.51 | -0.75 | -1.14 | -0.63 |
| Operating CF | (46.24M) | (40.01M) | (39.38M) | (32.88M) | (34.67M) | (29.08M) | (30.07M) | (21.16M) | (26.49M) | (39.60M) | (32.24M) | (32.76M) |
| Total Assets | 256.81M | 306.01M | 351.53M | 218.07M | 256.73M | 297.91M | 335.58M | 372.67M | 401.58M | 434.76M | 479.37M | 547.65M |
| Total Debt | 95.70M | 155.99M | 159.18M | 62.20M | 65.21M | 67.64M | 70.34M | 73.44M | 75.76M | 178.32M | 181.63M | 183.48M |
| Cash & Equiv | 125.90M | 169.53M | 209.86M | 72.04M | 104.17M | 138.85M | 168.07M | 197.86M | 219.22M | 245.92M | 285.51M | 345.67M |
| Book Value | 61.10M | 112.10M | 157.38M | 23.69M | 70.29M | 108.84M | 150.29M | 185.37M | 214.51M | 241.19M | 265.78M | 302.42M |
| Return on Equity | -1.07 | -0.52 | -0.36 | -2.59 | -0.77 | -0.53 | -0.29 | -0.24 | -0.21 | -0.18 | -0.22 | -0.17 |
